Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| C4 Therapeutics, Inc.CCCC · Entity 5503 | Chief Medical Officer | January 30, 2023 | February 01, 2023 |
| Tango Therapeutics, Inc.TNGX · Entity 1497 | President, R&D | October 01, 2026 | October 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
C4 Therapeutics, Inc.
Report date January 30, 2023 · Filed February 01, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,097 |
Ending reported balance
After 2023-01-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-01-30 · Exercise / conversion · Acquired 3,750 · Balance 21,398 F1: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Row 2 · 2023-01-30 · Tax withholding · Disposed 1,301 · Balance 20,097 F2: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2025-02-28 | Direct | 18,750 |
Reported balance
After 2023-01-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-01-30 · Exercise / conversion · Disposed 3,750 · Balance 18,750 F1: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. |
Filing footnotes · ownership attribution and instrument terms
F1: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones.
F2: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person.
Tango Therapeutics, Inc.
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 115,743 |
Ending reported balance
After 2026-10-01 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-10-01 · Exercise / conversion · Acquired 27,000 · Balance 142,743 F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025. Row 2 · 2026-10-01 · Sale · Disposed 26,400 · Balance 116,343 F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025. F2: Represents the weighted average sales price per share. The shares sold at prices ranging from $23.96 to $24.95 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 3 · 2026-10-01 · Sale · Disposed 600 · Balance 115,743 F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025. F3: Represents the weighted average sales price per share. The shares sold at prices ranging from $25.04 to $25.41 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.20 · Expires 2033-03-01 | Direct | 233,040 |
Reported balance
After 2026-10-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-10-01 · Exercise / conversion · Disposed 27,000 · Balance 233,040 F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025. F4: This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025.
F2: Represents the weighted average sales price per share. The shares sold at prices ranging from $23.96 to $24.95 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F3: Represents the weighted average sales price per share. The shares sold at prices ranging from $25.04 to $25.41 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F4: This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 30, 2023 Filed Feb 1, 2023 21:11 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 1,301 | $7.78 | $10,121.78 |
DisclosureSEC source: 0001662579-23-000024 · wf-form4_167528585798757.xml · nonDerivative · entry 2 Crystal Adam · CIK 0001825445 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,097 F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 21:11 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001662579-23-000024 · wf-form4_167528585798757.xml · nonDerivative · entry 1 Crystal Adam · CIK 0001825445 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,398 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| May 26, 2022 Filed Jun 14, 2022 20:45 UTC Amendment | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 1,102 | $7.01 | $7,725.02 |
DisclosureSEC source: 0001209191-22-036712 · doc4a.xml · nonDerivative · entry 1 Crystal Adam · CIK 0001825445 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,648 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of performance restricted stock units and does not represent a sale by the Reporting Person. Read SEC document |
| May 25, 2022 Filed May 27, 2022 20:16 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionPerformance Restricted Stock Units · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-032514 · doc4.xml · derivative · entry 2 Crystal Adam · CIK 0001825445 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 3,750 shares Expires 2025-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. F1 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| May 25, 2022 Filed May 27, 2022 20:16 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-032514 · doc4.xml · nonDerivative · entry 1 Crystal Adam · CIK 0001825445 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 21:30 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantPerformance Restricted Stock Units · Derivative | 26,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-010204 · doc4.xml · derivative · entry 2 Crystal Adam · CIK 0001825445 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,250 Underlying: Common Stock · 26,250 shares Expires 2025-02-28 F2 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining 21,750 PRSUs shall vest upon satisfaction of certain discovery and clinical milestones. F2 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining 21,750 PRSUs shall vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 21:30 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 118,000 | $0.00 Strike: $22.71 | $0.00 |
DisclosureSEC source: 0001209191-22-010204 · doc4.xml · derivative · entry 1 Crystal Adam · CIK 0001825445 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,000 Underlying: Common Stock · 118,000 shares Expires 2032-02-13 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 14, 2022. Read SEC document |
| January 04, 2022 Filed Jan 5, 2022 21:30 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $6.49 | $0.00 |
DisclosureSEC source: 0001209191-22-001700 · doc4.xml · derivative · entry 4 Crystal Adam · CIK 0001825445 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,292 Underlying: Common Stock · 15,000 shares Expires 2029-04-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on January 21, 2021. F4 · derivative.exercise_date: 25% of this option vested and became exercisable on February 14, 2020, with the remainder vesting in 16 equal quarterly installments thereafter. Read SEC document |
| January 04, 2022 Filed Jan 5, 2022 21:30 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 1,054 | $32.66 | $34,420.48 |
DisclosureSEC source: 0001209191-22-001700 · doc4.xml · nonDerivative · entry 3 Crystal Adam · CIK 0001825445 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on January 21, 2021. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.32 to $33.20. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 04, 2022 Filed Jan 5, 2022 21:30 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 13,946 | $31.59 | $440,547.17 |
DisclosureSEC source: 0001209191-22-001700 · doc4.xml · nonDerivative · entry 2 Crystal Adam · CIK 0001825445 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,054 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on January 21, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.00 to $31.90. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 04, 2022 Filed Jan 5, 2022 21:30 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 15,000 | $6.49 | $97,350.00 |
DisclosureSEC source: 0001209191-22-001700 · doc4.xml · nonDerivative · entry 1 Crystal Adam · CIK 0001825445 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on January 21, 2021. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 21:10 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $6.49 | $0.00 |
DisclosureSEC source: 0001209191-21-071069 · doc4.xml · derivative · entry 2 Crystal Adam · CIK 0001825445 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,292 Underlying: Common Stock · 5,000 shares Expires 2029-04-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of this option vested and became exercisable on February 14, 2020, with the remainder vesting in 16 equal quarterly installments thereafter. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 21:10 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 5,000 | $6.49 | $32,450.00 |
DisclosureSEC source: 0001209191-21-071069 · doc4.xml · nonDerivative · entry 1 Crystal Adam · CIK 0001825445 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 08, 2021 Filed Oct 12, 2021 20:30 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $6.49 | $0.00 |
DisclosureSEC source: 0001209191-21-060230 · doc4.xml · derivative · entry 2 Crystal Adam · CIK 0001825445 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,292 Underlying: Common Stock · 10,000 shares Expires 2029-04-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of this option vested and became exercisable on February 14, 2020, with the remainder vesting in 16 equal quarterly installments thereafter. Read SEC document |
| October 08, 2021 Filed Oct 12, 2021 20:30 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 10,000 | $6.49 | $64,900.00 |
DisclosureSEC source: 0001209191-21-060230 · doc4.xml · nonDerivative · entry 1 Crystal Adam · CIK 0001825445 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 20:53 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $4.98 | $0.00 |
DisclosureSEC source: 0001209191-21-059512 · doc4.xml · derivative · entry 5 Crystal Adam · CIK 0001825445 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,108 Underlying: Common Stock · 15,000 shares Expires 2030-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option shall vest and become exercisable in 20 equal quarterly installments, with the first installment vesting on September 5, 2020. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 20:53 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 5,112 | $45.99 | $235,118.77 |
DisclosureSEC source: 0001209191-21-059512 · doc4.xml · nonDerivative · entry 4 Crystal Adam · CIK 0001825445 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on January 21, 2021. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.89 to $46.30. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 20:53 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 8,176 | $45.32 | $370,563.30 |
DisclosureSEC source: 0001209191-21-059512 · doc4.xml · nonDerivative · entry 3 Crystal Adam · CIK 0001825445 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,112 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on January 21, 2021. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $44.85 to $45.845. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 20:53 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 1,712 | $44.25 | $75,756.34 |
DisclosureSEC source: 0001209191-21-059512 · doc4.xml · nonDerivative · entry 2 Crystal Adam · CIK 0001825445 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,288 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on January 21, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $43.57 to $44.56. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 20:53 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 15,000 | $4.98 | $74,700.00 |
DisclosureSEC source: 0001209191-21-059512 · doc4.xml · nonDerivative · entry 1 Crystal Adam · CIK 0001825445 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 29, 2021 Filed Aug 2, 2021 22:44 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $4.98 | $0.00 |
DisclosureSEC source: 0001209191-21-049114 · doc4.xml · derivative · entry 3 Crystal Adam · CIK 0001825445 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,108 Underlying: Common Stock · 15,000 shares Expires 2030-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option shall vest and become exercisable in 20 equal quarterly installments, with the first installment vesting on September 5, 2020. Read SEC document |
| July 29, 2021 Filed Aug 2, 2021 22:44 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 15,000 | $45.00 | $675,000.00 |
DisclosureSEC source: 0001209191-21-049114 · doc4.xml · nonDerivative · entry 2 Crystal Adam · CIK 0001825445 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on January 21, 2021. Read SEC document |
| July 29, 2021 Filed Aug 2, 2021 22:44 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 15,000 | $4.98 | $74,700.00 |
DisclosureSEC source: 0001209191-21-049114 · doc4.xml · nonDerivative · entry 1 Crystal Adam · CIK 0001825445 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2021 Filed Jul 7, 2021 00:00 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $6.50 | $0.00 |
DisclosureSEC source: 0001209191-21-045691 · doc4.xml · derivative · entry 4 Crystal Adam · CIK 0001825445 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,292 Underlying: Common Stock · 15,000 shares Expires 2029-04-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on January 21, 2021. F3 · derivative.exercise_date: 25% of this option vested and became exercisable on February 14, 2020, with the remainder vesting in 16 equal quarterly installments thereafter. Read SEC document |
| July 01, 2021 Filed Jul 7, 2021 00:00 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 1,700 | $38.38 | $65,246.00 |
DisclosureSEC source: 0001209191-21-045691 · doc4.xml · nonDerivative · entry 3 Crystal Adam · CIK 0001825445 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on January 21, 2021. Read SEC document |
| July 01, 2021 Filed Jul 7, 2021 00:00 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 13,300 | $37.93 | $504,419.79 |
DisclosureSEC source: 0001209191-21-045691 · doc4.xml · nonDerivative · entry 2 Crystal Adam · CIK 0001825445 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,700 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on January 21, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.33 to $38.25. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 01, 2021 Filed Jul 7, 2021 00:00 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 15,000 | $6.50 | $97,500.00 |
DisclosureSEC source: 0001209191-21-045691 · doc4.xml · nonDerivative · entry 1 Crystal Adam · CIK 0001825445 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on January 21, 2021. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 20:30 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock · Derivative | 15,000 | $0.00 Strike: $6.50 | $0.00 |
DisclosureSEC source: 0001209191-21-025664 · doc4.xml · derivative · entry 4 Crystal Adam · CIK 0001825445 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,292 Underlying: Common Stock · 15,000 shares Expires 2029-04-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on January 21, 2021. F4 · derivative.exercise_date: 25% of this option vested and became exercisable on February 14, 2020, with the remainder vesting in 16 equal quarterly installments thereafter. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 20:30 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 10,879 | $38.00 | $413,407.44 |
DisclosureSEC source: 0001209191-21-025664 · doc4.xml · nonDerivative · entry 3 Crystal Adam · CIK 0001825445 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on January 21, 2021. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.59 to $38.32. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 20:30 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 4,121 | $37.16 | $153,128.53 |
DisclosureSEC source: 0001209191-21-025664 · doc4.xml · nonDerivative · entry 2 Crystal Adam · CIK 0001825445 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,879 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on January 21, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.545 to $37.53. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 20:30 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 15,000 | $6.50 | $97,500.00 |
DisclosureSEC source: 0001209191-21-025664 · doc4.xml · nonDerivative · entry 1 Crystal Adam · CIK 0001825445 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on January 21, 2021. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 21:15 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 87,850 | $0.00 Strike: $45.54 | $0.00 |
DisclosureSEC source: 0001209191-21-010707 · doc4.xml · derivative · entry 1 Crystal Adam · CIK 0001825445 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,850 Underlying: Common Stock · 87,850 shares Expires 2031-02-10 F1 · derivative.exercise_date: This option shall vest and become exercisable in 16 equal quarterly installments, with the first installment vesting on May 11, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.